SCHEMBL969758

SCHEMBL969758

COc1ccc(CC(=O)O)cc1C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.70
ALDH1A1 P00352 2/20 0.65
TSHR P16473 2/20 0.65
NFKB1 P19838 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
CA5A P35218 1/20 0.60
PTGS1 P23219 1/20 0.56
AKR1C3 P42330 1/20 0.56
AKR1C2 P52895 1/20 0.56
NPSR1 Q6W5P4 1/20 0.54
HSD17B10 Q99714 2/20 0.51
HPGD P15428 2/20 0.50
SELL P14151 1/20 0.50
SELP P16109 1/20 0.50
SLC22A12 Q96S37 1/20 0.50
CACNA1G O43497 1/20 0.49
CACNA1H O95180 1/20 0.49
CACNA1I Q9P0X4 1/20 0.49
SRD5A2 P31213 1/20 0.48
LDHA P00338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30094539 1.00 GAA (0.70) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL4082027 0.86 GAA (0.51) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL1010618 0.86 GAA (0.70) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL153055 0.85 GAA (0.74) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL30049382 0.85 GAA (0.74) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL11474437 0.85 MRGPRX4 (0.57) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL9724448 0.84 GAA (0.50) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL3759057 0.84 GAA (0.53) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL3659918 0.84 GAA (0.50) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL17653849 0.84 EPHX2 (0.52) GAAALDH1A1TSHRNFKB1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-07-20 US disclosed
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 EP disclosed
EP-4121425-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 EP disclosed
CN-115551845-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-30 CN disclosed
CN-115515948-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-23 CN disclosed
WO-2021188936-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
US-10857155-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2020-12-08 US disclosed
US-10406165-B2 Compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2019-09-10 US disclosed
US-6294558-B1 ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS PFIZER INC. 2001-09-25 US disclosed
EP-1086097-A1 SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS PFIZER INC. (US) 2001-03-28 EP disclosed
WO-2000055137-A1 COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS SIGNAL PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed
EP-1000008-A1 NOVEL THYROID RECEPTOR LIGANDS AND METHOD KARO BIO AB (SE) 2000-05-17 EP disclosed
WO-1999064415-A1 SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 1999-12-16 WO disclosed
WO-1999000353-A1 NOVEL THYROID RECEPTOR LIGANDS AND METHOD KARO BIO AB (SE) 1999-01-07 WO disclosed
US-5674909-A FOR TREATMENT OF CARDIOVASCULAR DISORDERS ZAMBON GROUP (IT) 1997-10-07 US disclosed
EP-0781126-A2 DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM ZAMBON GROUP S.p.A. (IT) 1997-07-02 EP disclosed
WO-1996008228-A2 DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM ZAMBON GROUP S.P.A. (IT) 1996-03-21 WO disclosed
US-5230975-A Photoconductive imaging members with unsymmetrical alkylalkoxy squaraine compositions XEROX CORPORATION (US) 1993-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 GAA 3880/4885ALDH1A1 989/4885TSHR 4422/4885
US-10857155-B2 Compounds targeting proteins, compositions, methods, and uses thereof GSPT1, GSPT2, GGT1 GAA 803/4885ALDH1A1 3918/4885TSHR 3493/4885
US-10406165-B2 Compounds targeting proteins, compositions, methods, and uses thereof GSPT1, GSPT2, GGT1 GAA 803/4885ALDH1A1 3918/4885TSHR 3493/4885
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 GAA 3851/4885ALDH1A1 963/4885TSHR 4420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.